|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||34.32 / 46.47|
Focus on high-quality dividend payers as we move toward a possible yield-curve inversion and U.S. recession.
Kineta Immuno-Oncology to receive $15 million upfront and will be eligible to receive up to $505 million in potential research, development and sales milestone payments
Johnson & Johnson shares plunged the most in more than 15 years Friday following a report that said the company knew for decades that its iconic baby powder sometimes contained asbestos and failed to alert authorities.
Pfizer shares traded lower Friday even as the pharmaceutical group boosted it latest quarterly dividend and said it would buyback another $10 million in company stock in what may be the last corporate act of outgoing CEO Ian Read.
The board of directors of Pfizer Inc. today declared a 36-cent first-quarter 2019 dividend on the company's common stock, payable March 1, 2019, to shareholders of record at the close of business on February 1, 2019.
Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for ZIRABEV ™ (bevacizumab), a potential...
Pfizer Inc. (NYSE:PFE) announced today the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes...
The most recent short interest data has been released for the 11/30/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Stocks are mixed Tuesday as Donald Trump and top Democratic leaders clash over border security.
The CEOs who bring in the most money every year may not be who you expect. Who are the highest-paid CEOs?
Pfizer shares slipped Tuesday after analysts at JPMorgan lowered their rating for the drugmaker amid concerns of the loss of exclusivity on one of its key pain treatments.
Global stocks edged higher Tuesday, with investors reacting cautiously to progress in U.S.-China trade talks but still unnerved by the ongoing political chaos surrounding Britain's Brexit vote, as bond investor prep for a series of Treasury auctions in the United States.
Pfizer Inc. (NYSE:PFE) announced today at the American Society of Hematology Annual Meeting that the REFLECTIONS B328-06 study, a comparative safety and efficacy study of PF-05280586 versus Rituxan ®/MabThera ® (rituximab-EU) i, met its primary endpoint...
This healthcare stock looks healthy for your portfolio amid the volatility.
Pfizer Inc. (NYSE:PFE) today announced that it has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar.
Pfizer Inc. (NYSE: PFE) today announced that the U.
Pfizer Inc. (NYSE:PFE) today announced that the U.
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Chris Boshoff, senior vice president and head, Immuno-Oncology, Early Development and Translational Oncology, at the Evercore ISI HealthConX Conference on...
Pfizer pushes higher on price increases.
A retest of the October lows seems almost too obvious but it is hard to dispute the possibility that it may occur.
Pharma could be the best parking spot for your money if the market keeps trending downward.
Worried about the market? Jim Cramer has some advice for investors.
Shares of the New York City-based pharmaceutical giant are rising on Monday.
Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Jim Cramer responds to the news that the drug company, Pfizer, has hiked rates.
Let's check our indicators.
DARMSTADT, Germany and NEW YORK, November 19, 2018 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany, and Pfizer Inc.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.